Abstract / Summary
Abstract Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) globally, and its burden is growing disproportionately in lower-middle-income countries where detection and management infrastructure remain limited. In Kyrgyzstan, a Central Asian republic with a resource-constrained healthcare system, type 2 diabetes mellitus (T2DM) is increasingly prevalent among adults, yet DKD remains critically underrecognized and undertreated. Systematic urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) screening is inconsistently implemented in routine primary care across most oblasts, nephrology services are concentrated almost exclusively in the capital, and key cardiorenal protective pharmacological agents — specifically sodium-glucose cotransporter-2 (SGLT2) inhibitors and non-steroidal mineralocorticoid receptor antagonists (MRAs) — are absent from the national Essential Medicines List (EML). This narrative review synthesizes global and Kyrgyzstan-specific evidence on the epidemiology, pathophysiology, diagnostic assessment, cardiorenal complications, and management of DKD in a resource-limited Central Asian setting. A structured literature search was conducted across PubMed/MEDLINE, the Cochrane Library, international clinical practice guidelines, and Kyrgyz Ministry of Health clinical databases. A substantial proportion of Kyrgyz adults with T2DM are estimated to have concurrent DKD, with the majority presenting at advanced CKD stages at the time of first nephrology referral — a pattern reflecting systematic late detection rather than low disease burden. Renin-angiotensin-aldosterone system (RAAS) blockade with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs), which are available and affordable within the Kyrgyz healthcare system, provides meaningful renoprotection but remains underutilized due to absent screening pathways. SGLT2 inhibitors, which have demonstrated robust kidney- and cardiovascular-protective effects in large international trials, represent the most critical pharmacological gap in Kyrgyz DKD management. Priority system-level interventions identified in this review include universal annual UACR and eGFR screening for all T2DM patients, task-shifting of DKD monitoring to primary care providers, inclusion of SGLT2 inhibitors on the national EML, and establishment of a national diabetic nephropathy registry. Addressing DKD systematically represents the single highest-impact opportunity to reduce the growing ESKD burden on Kyrgyzstan's national healthcare system and to prevent premature cardiorenal mortality in the Kyrgyz diabetic population. Keywords: diabetic kidney disease; Kyrgyzstan; chronic kidney disease; type 2 diabetes mellitus; SGLT2 inhibitors; albuminuria; glomerular filtration rate; Central Asia; cardiorenal syndrome; resource-limited settings Introduction Diabetic kidney disease (DKD) — defined as CKD occurring in the context of diabetes mellitus, characterized by persistently elevated urinary albumin excretion, reduced eGFR, or both — is the most prevalent microvascular complication of type 2 diabetes mellitus (T2DM) and the most common cause of end-stage kidney disease (ESKD) requiring renal replacement therapy in most countries worldwide. [1] The International Diabetes Federation (IDF) estimates that DKD affects approximately 40% of individuals with T2DM globally, translating to over 200 million people living with concurrent diabetes and kidney disease. The cardiorenal consequences of DKD — including a 2–4-fold excess cardiovascular mortality, premature progression to dialysis, and catastrophic healthcare expenditure — make it one of the most costly and consequential non-communicable disease complications of the 21st century. [1,2] Kyrgyzstan — a landlocked Central Asian republic with a population of approximately 7.3 million, a gross national income per capita of approximately USD 1,280 (2023), and a healthcare system structured around inherited Soviet-era infrastructure — presents a deeply concerning DKD epidemiological landscape that has received insufficient research and policy attention. T2DM prevalence, estimated at 7.9% of Kyrgyz adults by the IDF Diabetes Atlas 10th Edition, has risen steadily in parallel with urbanization, nutritional transition toward high-glycemic dietary patterns, and growing rates of overweight and abdominal obesity. [3] The Kyrgyz Ministry of Health National Protocol for T2DM (2021 revision) nominally recommends annual kidney function testing, but implementation is inconsistent across primary care facilities in all seven oblasts, and no national DKD registry exists. [4] The clinical urgency of addressing DKD in Kyrgyzstan has been substantially amplified by two landmark developments in global nephrology. First, the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD — the most authoritative international evidence synthesis to date — established SGLT2 inhibitors as a first-line DKD-protective agent alongside RAAS blockade, based on trials demonstrating 34–39% reduction in kidney failure risk (CREDENCE, DAPA-CKD, EMPA-KIDNEY). [5] Second, the FIDELIO-DKD trial established finerenone, a non-steroidal MRA, as a further additive renoprotective agent in DKD patients already receiving optimized RAAS blockade. [6] Neither SGLT2 inhibitors nor finerenone are accessible on the Kyrgyz national EML, creating a widening evidence-to-practice gap with direct and preventable consequences for Kyrgyz patients with T2DM and CKD. [4] The objectives of this narrative review are: (1) to characterize the epidemiological burden of DKD in Kyrgyzstan in global context; (2) to review DKD pathophysiology and KDIGO-aligned diagnostic criteria; (3) to document cardiorenal complications and ESKD consequences; (4) to present an evidence-based management framework stratified by therapeutic availability within Kyrgyzstan; and (5) to identify priority health system interventions for closing the DKD detection and treatment gap. Review Methodology This narrative review was conducted following a structured, pre-defined literature search strategy. Electronic databases searched included PubMed/MEDLINE, the Cochrane Library, the KDIGO guideline repository, the WHO Global Health Library, the IDF Diabetes Atlas (10th Edition, 2021), and the Kyrgyz Ministry of Health clinical protocol database. Reference lists of all included systematic reviews and meta-analyses were hand-searched for additional relevant primary studies. Search terms were applied using Boolean operators in English and Russian languages: "diabetic kidney disease" AND "Kyrgyzstan"; "diabetic nephropathy" AND "Central Asia"; "CKD" AND "type 2 diabetes" AND "epidemiology"; "SGLT2 inhibitors" AND "DKD"; "albuminuria screening" AND "low- and middle-income countries"; "cardiorenal syndrome" AND "diabetes"; "RAAS blockade" AND "diabetic nephropathy"; "KDIGO guidelines" AND "diabetes management." Inclusion criteria encompassed: systematic reviews and meta-analyses of DKD epidemiology, pathophysiology, or outcomes; randomized controlled trials with sample sizes of 200 or more participants; prospective cohort studies with minimum 300 participants; international clinical practice guidelines published 2010–2024; and national registry data and official government or international organization reports. Articles available only in abstract form, conference proceedings without peer review, and case reports were excluded. Landmark trials published before 2010 (RENAAL [2001], IDNT [2001], ADVANCE [2008], ACCORD [2010]) were included given their foundational role in establishing DKD management standards. Global and Regional Epidemiology of Diabetic Kidney Disease Global Burden DKD represents the leading etiology of ESKD in most high-, middle-, and many low-income countries, having overtaken hypertensive nephropathy and primary glomerulonephritis in prevalence over the past three decades. [1,2] The IDF Diabetes Atlas 10th Edition estimates that 40.0% of the global T2DM population — over 200 million individuals — has some degree of DKD, spanning from early albuminuria with preserved eGFR to advanced CKD stages 4–5 requiring imminent renal replacement. [1] Annual global incident ESKD attributable to diabetic nephropathy exceeds 200,000 cases, generating direct renal replacement therapy costs estimated at USD 35–50 billion annually in high-income countries — a figure that, even at dramatically lower unit cost, represents an unsustainable financial burden for LMICs. [2,7] Central Asia — classified as a distinct IDF region — carries an estimated T2DM prevalence of 10.1% (2021) and a correspondingly significant DKD burden, though nationally representative DKD prevalence data from individual Central Asian republics remain sparse. [3] Figure 1 illustrates T2DM prevalence trends (2010–2035) for Kyrgyzstan, the Central Asian regional average, and the global average (Panel A), alongside CKD stage distribution among T2DM patients in Kyrgyzstan compared to the global average (Panel B), based on IDF Atlas data [1,3] and published epidemiological studies. [2,8] Figure 1. T2DM Prevalence Trends and CKD Stage Distribution in T2DM Patients. Panel A: Estimated T2DM prevalence trends (2010–2035) for Kyrgyzstan, the Central Asian regional average, and the global average; shaded zone indicates projected values beyond 2024. Panel B: CKD stage distribution (KDIGO classification) among T2DM patients in Kyrgyzstan versus the global average; notably, advanced stages G3b–G5 are disproportionately represented in Kyrgyzstan, reflecting late-stage detection patterns. Figures created by the authors using Python (matplotlib v3.7). Data: IDF Diabetes Atlas, 10th Edition (2021) [1,3]; GBD 2021 Diabetes Collaborators, Lancet (2023) [2]. DKD in Kyrgyzstan: Epidemiological Overview Systematic nationall